Expert Interview
Discussing Pharvaris' PHVS416 in treating Hereditary angioedema attacks
Ticker(s): PHVSInstitution: Allergy Specialists
- Board certified Internist and Allergist in private practice in Dallas, Texas treating adults and children with allergic diseases and asthma.
- Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical School in Dallas and teaches at Parkland Memorial and Presbyterian Hospitals in Dallas.
- Follows 140 type 1 and 2 patients with HAE.
- Member of the U.S. Hereditary Angioedema Association and on the panel responsible for the HAWK, ICON and WAO hereditary angioedema consensus documents.
Please describe your practice as a clinician,how many patients with HAE do you see on a yearly basis? How many present with acute attacks to the hospital? Could you walk us through the standard of care and take us through the most promising upcoming treatments, or interesting clinical trials in this space?
Added By: slingshot_insightsHow well do patients respond to acute therapies, coupled with prophylactic treatment? How much of an unmet need does still remain?
Could you please comment on the results where PHVS416 shortens the time to onset of symptom relief by a greater than or equal to30% reduction ; decreases time to a greater than or equal to 50% reduction in VAS-3 score; reduces time to almost complete or complete symptom relief by VAS-3; reduces mean symptom complex severity score from pre-treatment to four hours post-treatment.
What is your impression on the reduction of attack symptoms reported in the trial, how does it compare to standard of care, in terms of oral, on demand medication?
How plausible is the adoption of PHVS416 by your peers, as the treatment of choice for Hereditary angioedema attacks?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
